AbbVie (recently split off from Abbott Laboratories), maker of Humira, and InterMune, maker of Esbriet, have filed a lawsuit against the European Medicines Agency (the European equivalent of the FDA) to block access to clinical trial data on the benefits and harms of their drugs, claiming that these vital facts are “trade secrets” whose release would harm their profits. Medical researches have been denied to clinical trial information.
Of course, when a drug causes cancer, release of clinical data information could potentially harm the profits of the company that makes it. Humira, a drug that is quickly becoming one of the best-selling drugs in the world, mainly because of the marketing techniques used by AbbVie, causes cancer.
The FDA warning label on Humira warns of increased risk of “Lymphoma and other malignancies” including “a rare type of cancer called hepatosplenic T-cell lymphoma” that “often results in death,” along with “increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens.”